Archives: Agenda

• The biggest opportunities changing rare disease development
• How sponsors can accelerate development without increasing operational risk
• Emerging regulatory and scientific priorities
• Where collaboration will matter most over the next five years

• Balancing scientific objectives alongside cost, timelines and recruitment potential
• Understanding how standards of care and comparator availability influence country selection
• Exploring opportunities in emerging regions while maintaining study quality
• Selecting countries that improve both operational delivery and scientific validity

• The proposed framework
• Impact on rare disease developers
• Practical implications
• Questions from sponsors

Reserved for NIHR

• What the most advanced institutions are doing differently: lessons from AI programmes delivering at enterprise scale
• Sequencing the journey: foundations, first wins, scaling and continuous improvement
• Preparing for what comes next: agentic AI, autonomous operations and the changing shape of the technology stack

• Upskilling at scale: building AI literacy across the whole organisation, not just the technology function
• The new roles emerging in the AI-enabled enterprise, from prompt engineers to AI product owners
• Competing for scarce talent: recruitment, retention and the case for growing your own
• Redesigning roles and career paths as AI reshapes the day-to-day work of your teams

• Navigating the real-world blockers: legacy technology, data silos, budget constraints and cultural resistance
• Securing stakeholder buy-in: bringing risk, compliance and the front office along on the journey
• Managing vendor relationships and avoiding lock-in as the market evolves at pace
• How to fail fast, learn quickly and keep momentum when projects hit turbulence